Erdaini(Erdafitinib)

What Erdaini (Erdafitinib) is

Erdaini (Erdafitinib) belongs to a class of cancer medicines called fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor It contains the active substance Erdaini (Erdafitinib).

 What Erdaini (Erdafitinib) is used for

Erdaini (Erdafitinib) is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery:

 . which has a certain type of abnormal “FGFR” gene, and

 . who have tried at least one other chemotherapy medicine that contains platinum, and it did not work or is no longer working.

How Erdaini (Erdafitinib) works

Erdaini (Erdafitinib) is a kinase inhibitor that binds to and inhibits enzymatic activity of FGFR1, FGFR2, FGFR3 and FGFR4 based on in vitro data. Erdaini also binds to RET, CSF1R, PDGFRA, PDGFRB, FLT4, KIT, and VEGFR2. Erdaini inhibited FGFR phosphorylation and signaling and decreased cell viability in cell lines expressing FGFR genetic alterations, including point mutations, amplifications, and fusions. Erdaini demonstrated antitumor activity in FGFR-expressing cell lines and xenograft models derived from tumor types, including bladder cancer.